3种宫缩抑制剂治疗先兆早产的临床疗效分析  

Analysis on clinical effect of three types of uterine contraction inhibitors to treat threatened premature delivery

作　　者：骆绮云[1] 蒙顺好[1] 叶穗雯[1] 付帅[1] 龙庆麟[1] 陈慧[1] 

机构地区：[1]中山大学孙逸仙纪念医院,广东广州510120

出　　处：《现代医药卫生》2012年第7期969-970,共2页Journal of Modern Medicine & Health

基　　金：中山大学医科青年教师科研启动基金(2007016);广东高校优秀青年创新人才培育项目(粤财教【2008】342号)

摘　　要：目的探讨利托君、阿托西班、硫酸镁3种宫缩抑制剂治疗先兆早产的临床疗效。方法将100例先兆早产孕妇随机分为3组,其中利托君组40例,阿托西班组30例,硫酸镁组30例,观察孕妇用药后的显效时间、保胎成功率、不良反应等。结果利托君组与阿托西班组的显效时间、保胎成功率、延长妊娠时间、足月分娩率、新生儿出生体质量互相比较,差异均无统计学意义(P>0.05),但两组均显著优于硫酸镁组,差异有统计学意义(P<0.05);3组间的不良反应发生率差异无统计学意义(P>0.05)。结论利托君、阿托西班、硫酸镁均能有效抑制宫缩,用药安全。对于治疗先兆早产,利托君、阿托西班明显优于硫酸镁。两者作用相当,但利托君价格低廉,可作为治疗先兆早产的首选药物。Objective To investigate the clinical effects of 3 types of uterine contractions inhibitors, ritodrine, atosiban and magnesium sulfate ,to treat threatened premature delivery. Methods 100 pregnant women with threatened premature deliv- ery were randomly divided into 3 groups, ritodrine group （40 cases）, atosiban group （30 cases） and magnesium sulfate group （30 cases）. The time-to-effect,success rate of fetus protection and the adverse reactions after medication were observed among 3 groups. Results The ritodrine group and the atosiban group showed no statistical difference by comparison with each other in the aspects of the time-to-effect, success rate of fetus protection, prolonged pregnancy duration, full-term delivery rate and .neonatal weight （P〉0.05）. But the two groups were significantly better than the magnesium sulfate group with statistical difference （P〈0.05）. There were no statistical differences in the incidence rate of adverse reactions among 3 groups. Conclusion Ritodrine, atosiban and magnesium sulfate all can effectively restrain uterine contractions with safe medication. For the treatment of threatened prema- ture labor, ritodrine and atosiban are superior to magnesium sulfate. These 2 drugs have similar effects, but ritodrine can be used as the first choice to treat threatened premature delivery due to its lower cost.

关 键 词：先兆早产 利托君 阿托西班 硫酸镁 治疗结果 对比研究 

分 类 号：R719.31[医药卫生—妇产科学]